Clarity Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Clarity Pharmaceuticals's earnings have been declining at an average annual rate of -36.9%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 36.5% per year.
Key information
-36.9%
Earnings growth rate
-26.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 36.5% |
| Return on equity | -28.9% |
| Net Margin | -296.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Jan 03
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow
May 29Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Aug 24Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation
Jan 13Revenue & Expenses Breakdown
How Clarity Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 14 | -42 | 11 | 46 |
| 31 Mar 24 | 12 | -36 | 8 | 41 |
| 31 Dec 23 | 9 | -31 | 6 | 36 |
| 30 Sep 23 | 10 | -28 | 5 | 34 |
| 30 Jun 23 | 10 | -25 | 5 | 31 |
| 31 Mar 23 | 10 | -23 | 5 | 29 |
| 31 Dec 22 | 9 | -21 | 5 | 26 |
| 30 Sep 22 | 8 | -23 | 5 | 23 |
| 30 Jun 22 | 6 | -24 | 5 | 19 |
| 31 Mar 22 | 6 | -21 | 5 | 16 |
| 31 Dec 21 | 5 | -19 | 5 | 12 |
| 30 Sep 21 | 4 | -15 | 4 | 11 |
| 30 Jun 21 | 3 | -10 | 4 | 10 |
| 31 Mar 21 | 3 | -9 | 3 | 10 |
| 31 Dec 20 | 3 | -9 | 2 | 10 |
| 30 Sep 20 | 3 | -8 | 2 | 8 |
| 30 Jun 20 | 3 | -7 | 3 | 7 |
| 30 Jun 19 | 3 | -4 | 3 | 2 |
| 30 Jun 18 | 2 | -2 | 2 | 1 |
Quality Earnings: CU6 is currently unprofitable.
Growing Profit Margin: CU6 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CU6 is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.
Accelerating Growth: Unable to compare CU6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CU6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Return on Equity
High ROE: CU6 has a negative Return on Equity (-28.93%), as it is currently unprofitable.